Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

ClinicalTrials.gov ID: NCT02830542

Public ClinicalTrials.gov record NCT02830542. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence

Study identification

NCT ID
NCT02830542
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Seres Therapeutics, Inc.
Industry
Enrollment
96 participants

Conditions and interventions

Interventions

  • SER-262 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2016
Primary completion
Apr 30, 2018
Completion
Jul 31, 2018
Last update posted
Feb 5, 2023

2016 – 2018

United States locations

U.S. sites
22
U.S. states
17
U.S. cities
22
Facility City State ZIP Site status
North Alabama Research Center, LLC Athens Alabama 35749
Lalla-Reddy Medical Corporation Fountain Valley California 92708
eStudySite La Mesa California 91942
San Marcus Research Clinic, Inc. Miami Florida 33015
Omega Research Consultants Orlando Florida 32810
Emory University Hospital Atlanta Georgia 30322
Clinical Research Atlanta Stockbridge Georgia 30281
Snake River Research Idaho Falls Idaho 83404
Anne Arundel Health System Research Institute Annapolis Maryland 21401
Henry Ford Health System Detroit Michigan 48202
Mayo Clinic Rochester Minnesota 55902
Sundance Clinical Research, LLC St Louis Missouri 63141
Mercury St. Medical Group Butte Montana 59701
Quality Clinical Research Omaha Nebraska 68114
Jersey Shore University Medical Center Neptune City New Jersey 07753
University of Rochester Medical Center Rochester New York 14642
Montefiore Medical Center The Bronx New York 10467
Remington Davis Columbus Ohio 43215
Regional Infectious Diseases & Infusion Center Lima Ohio 45801
Baylor Scott & White Research Institute Temple Texas 76508
Dr. Hansen Internal Medicine Bountiful Utah 84010
Infectious Disease Associates of Central Virginia Lynchburg Virginia 24501

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02830542, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 5, 2023 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02830542 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →